Cofetuzumab pelidotin

Cofetuzumab pelidotin
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	protein tyrosine kinase 7
Clinical data
Other names	PF-06647020
ATC code	none;
Identifiers
CAS Number	1869937-48-3;
ChemSpider	none;
UNII	249EAP69MT;
KEGG	D11118;
Chemical and physical data
Formula	C6774H10418N1778O2096S46
Molar mass	151776.97 g·mol−1

Cofetuzumab pelidotin (INN;[1] development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer.[2] The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.[3][4]

Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug that then kills the cells. This allows the drug to selectively target the cells that the antibody binds to.

PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer.[5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.[6]

References

World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin, American Medical Association.
"PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
"Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
"Antibody-Drug Conjugates (ADCs)" (PDF). Pfizer Oncology.
Patrick M (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. Retrieved 2017-05-22.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[WHOList117-1] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin, American Medical Association.

[3] "PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.

[4] "Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.

[5] "Antibody-Drug Conjugates (ADCs)" (PDF). Pfizer Oncology.

[6] Patrick M (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. Retrieved 2017-05-22.